{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:09:06Z","timestamp":1785902946923,"version":"3.56.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["71964003"],"award-info":[{"award-number":["71964003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100012547","name":"Natural Science Foundation of Guangxi Zhuang Autonomous Region","doi-asserted-by":"crossref","award":["2018JJA141048"],"award-info":[{"award-number":["2018JJA141048"]}],"id":[{"id":"10.13039\/100012547","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Research Foundation of the Science and Technology Department of Guangxi Province, China","award":["2016GXNSFAA380252"],"award-info":[{"award-number":["2016GXNSFAA380252"]}]},{"name":"Research Foundation of the Health Department of Guangxi Province, China","award":["S2018087"],"award-info":[{"award-number":["S2018087"]}]},{"name":"Guangxi Medical University Training Program for Distinguished Young Scholars"},{"name":"Medical Excellence Award Funded by the Creative Research Development Grant from the First Affiliated Hospital of Guangxi Medical University"},{"name":"Guangxi Medical High-level Talents Training Program. The central government guide local science and technology development projects","award":["ZY18057006"],"award-info":[{"award-number":["ZY18057006"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To retrospectively analyze the efficacy and safety of concurrent chemoradiotherapy (CCRT) plus recombinant human endostatin (Endostar, CCRT\u2009+\u2009E) versus CCRT alone in locally advanced nasopharyngeal carcinoma (LANPC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective analysis of patients initially treated for LANPC from November 2016 to March 2019 was performed: trial group received CCRT\u2009+\u2009E and control group received CCRT. Prognoses and adverse effects were evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Eighty-eight patients were included: 43 received CCRT\u2009+\u2009E and 45 received CCRT. The median follow-up time was 54.0 (range: 8.0\u201364.0) months. The survival data of the CCRT\u2009+\u2009E and CCRT groups were as follows: 3-year progression-free survival (PFS) rates, 81.4% and 63.6% (hazard ratio [HR] 0.418, 95%CI 0.181\u20130.963, <jats:italic>P<\/jats:italic>\u2009=\u20090.034); 3-year distant metastasis-free survival (DMFS) rates, 88.3% and 77.3% (HR 0.370, 95%CI 0.132\u20131.039, <jats:italic>P<\/jats:italic>\u2009=\u20090.049); 3-year overall survival rates, 88.2% and 81.9% (HR 0.437, 95%CI 0.151\u20131.260, <jats:italic>P<\/jats:italic>\u2009=\u20090.114); and 3-year locoregional failure-free survival rates, 87.8% and 86.9% (HR 0.795, 95%CI 0.242\u20132.616, <jats:italic>P<\/jats:italic>\u2009=\u20090.705). Three months after radiotherapy, the complete response (CR) rates of cervical lymph node regression were 97.7% and 82.2% for the CCRT\u2009+\u2009E and CCRT groups (<jats:italic>P<\/jats:italic>\u2009=\u20090.041). The corresponding CR rates were 100% and 80.0% for lymph node necrosis (<jats:italic>P<\/jats:italic>\u2009=\u20090.001) and 100% and 85.2% for extranodal extension (<jats:italic>P<\/jats:italic>\u2009=\u20090.041). The CCRT\u2009+\u2009E group had higher incidence of grade 3\/4 leukopenia (32.6% vs. 13.3%, <jats:italic>P<\/jats:italic>\u2009=\u20090.031), with similar results for late toxicity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>CCRT\u2009+\u2009E significantly prolonged 3-year PFS and DMFS in LANPC, and patients had better lymph node regression.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-022-02104-4","type":"journal-article","created":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T20:02:43Z","timestamp":1659124963000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy of concurrent chemoradiotherapy plus Endostar compared with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study"],"prefix":"10.1186","volume":"17","author":[{"given":"Yuanxiu","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiru","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yating","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaolin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rensheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2287-8757","authenticated-orcid":false,"given":"Min","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,29]]},"reference":[{"issue":"10192","key":"2104_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","volume":"394","author":"Y Chen","year":"2019","unstructured":"Chen Y, Chan A, Le Q, et al. Nasopharyngeal carcinoma. Lancet (London, England). 2019;394(10192):64\u201380.","journal-title":"Lancet (London, England)"},{"issue":"1","key":"2104_CR2","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s40880-017-0257-9","volume":"36","author":"K Wei","year":"2017","unstructured":"Wei K, Zheng R, Zhang S, et al. Nasopharyngeal carcinoma incidence and mortality in China, 2013. Chin J Cancer. 2017;36(1):90.","journal-title":"Chin J Cancer"},{"key":"2104_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.oraloncology.2017.12.004","volume":"77","author":"K Au","year":"2018","unstructured":"Au K, Ngan R, Ng A, et al. Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: a report of 3328 patients (HKNPCSG 1301 study). Oral Oncol. 2018;77:16\u201321.","journal-title":"Oral Oncol"},{"issue":"10054","key":"2104_CR4","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/S0140-6736(16)31388-5","volume":"388","author":"L Zhang","year":"2016","unstructured":"Zhang L, Huang Y, Hong S, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet (London, England). 2016;388(10054):1883\u201392.","journal-title":"Lancet (London, England)"},{"issue":"2","key":"2104_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S1470-2045(11)70320-5","volume":"13","author":"L Chen","year":"2012","unstructured":"Chen L, Hu C, Chen X, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2012;13(2):163\u201371.","journal-title":"Lancet Oncol"},{"issue":"4","key":"2104_CR6","first-page":"283","volume":"8","author":"J Wang","year":"2005","unstructured":"Wang J, Sun Y, Liu Y, et al. Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Chin J Lung Cancer. 2005;8(4):283\u201390.","journal-title":"Chin J Lung Cancer"},{"issue":"1","key":"2104_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.bbrc.2007.06.155","volume":"361","author":"Y Ling","year":"2007","unstructured":"Ling Y, Yang Y, Lu N, et al. Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR\/Flk-1 of endothelial cells. Biochem Biophys Res Commun. 2007;361(1):79\u201384.","journal-title":"Biochem Biophys Res Commun"},{"key":"2104_CR8","doi-asserted-by":"crossref","unstructured":"Guan Y, Li A, Xiao W, et al. The efficacy and safety of endostar combined with chemoradiotherapy for patients with advanced, locally recurrent nasopharyngeal carcinoma. Oncotarget. 2015;6(32):33926\u201334.","DOI":"10.18632\/oncotarget.5271"},{"issue":"9","key":"2104_CR9","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/nrc1693","volume":"5","author":"Y Cao","year":"2005","unstructured":"Cao Y. Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. Nat Rev Cancer. 2005;5(9):735\u201343.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"2104_CR10","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/path.2523","volume":"218","author":"P Gao","year":"2009","unstructured":"Gao P, Zhou G, Zhang Q, et al. Lymphangiogenesis in gastric carcinoma correlates with prognosis. J Pathol. 2009;218(2):192\u2013200.","journal-title":"J Pathol"},{"issue":"10","key":"2104_CR11","first-page":"722","volume":"17","author":"L Shang","year":"2014","unstructured":"Shang L, Zhao J, Wang W, et al. Inhibitory effect of endostar on lymphangiogenesis in non-small cell lung cancer and its effect on circulating tumor cells. Chin J Lung Cancer. 2014;17(10):722\u20139.","journal-title":"Chin J Lung Cancer"},{"issue":"5","key":"2104_CR12","doi-asserted-by":"publisher","first-page":"976","DOI":"10.3892\/ol.2012.856","volume":"4","author":"J Zhou","year":"2012","unstructured":"Zhou J, Wang L, Xu X, et al. Antitumor activity of Endostar combined with radiation against human nasopharyngeal carcinoma in mouse xenograft models. Oncol Lett. 2012;4(5):976\u201380.","journal-title":"Oncol Lett"},{"issue":"6","key":"2104_CR13","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3727\/096504014X13983417587401","volume":"21","author":"T Jin","year":"2013","unstructured":"Jin T, Li B, Chen X. A phase II trial of Endostar combined with gemcitabine and cisplatin chemotherapy in patients with metastatic nasopharyngeal carcinoma (NCT01612286). Oncol Res. 2013;21(6):317\u201323.","journal-title":"Oncol Res"},{"issue":"6","key":"2104_CR14","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1038\/mt.2014.53","volume":"22","author":"W Ye","year":"2014","unstructured":"Ye W, Liu R, Pan C, et al. Multicenter randomized phase 2 clinical trial of a recombinant human endostatin adenovirus in patients with advanced head and neck carcinoma. Mol Ther. 2014;22(6):1221\u20139.","journal-title":"Mol Ther"},{"issue":"1","key":"2104_CR15","doi-asserted-by":"publisher","first-page":"100492","DOI":"10.1016\/j.currproblcancer.2019.06.007","volume":"44","author":"Y Li","year":"2020","unstructured":"Li Y, Tian Y, Jin F, et al. A phase II multicenter randomized controlled trial to compare standard chemoradiation with or without recombinant human endostatin injection (Endostar) therapy for the treatment of locally advanced nasopharyngeal carcinoma: long-term outcomes update. Curr Probl Cancer. 2020;44(1):100492.","journal-title":"Curr Probl Cancer"},{"issue":"11","key":"2104_CR16","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/cac2.12218","volume":"41","author":"LL Tang","year":"2021","unstructured":"Tang LL, Chen YP, Chen CB, et al. The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma. Cancer Commun (Lond, Engl). 2021;41(11):1195\u2013227.","journal-title":"Cancer Commun (Lond, Engl)"},{"issue":"5","key":"2104_CR17","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.yexcr.2005.11.015","volume":"312","author":"J Folkman","year":"2006","unstructured":"Folkman J. Antiangiogenesis in cancer therapy\u2013endostatin and its mechanisms of action. Exp Cell Res. 2006;312(5):594\u2013607.","journal-title":"Exp Cell Res"},{"issue":"3","key":"2104_CR18","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/carcin\/21.3.505","volume":"21","author":"R Kerbel","year":"2000","unstructured":"Kerbel R. Tumor angiogenesis: past, present and the near future. Carcinogenesis. 2000;21(3):505\u201315.","journal-title":"Carcinogenesis"},{"issue":"1","key":"2104_CR19","first-page":"47","volume":"18","author":"K Fujita","year":"2007","unstructured":"Fujita K, Sano D, Kimura M, et al. Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma. Oncol Rep. 2007;18(1):47\u201351.","journal-title":"Oncol Rep"},{"key":"2104_CR20","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2147\/OTT.S126159","volume":"10","author":"J Tan","year":"2017","unstructured":"Tan J, Jiang L, Cheng X, et al. Association between VEGF-460T\/C gene polymorphism and clinical outcomes of nasopharyngeal carcinoma treated with intensity-modulated radiation therapy. Onco Targets Ther. 2017;10:909\u201318.","journal-title":"Onco Targets Ther"},{"key":"2104_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1479-5876-6-1","volume":"6","author":"Y Li","year":"2008","unstructured":"Li Y, Hu C, Shao Q, et al. Elevated expressions of survivin and VEGF protein are strong independent predictors of survival in advanced nasopharyngeal carcinoma. J Transl Med. 2008;6:1.","journal-title":"J Transl Med"},{"issue":"1","key":"2104_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijrobp.2003.10.038","volume":"59","author":"D Chua","year":"2004","unstructured":"Chua D, Nicholls J, Sham J, et al. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59(1):11\u201320.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2104_CR23","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/annonc\/mdr116","volume":"23","author":"G Fountzilas","year":"2012","unstructured":"Fountzilas G, Ciuleanu E, Bobos M, et al. Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. Ann Oncol. 2012;23(2):427\u201335.","journal-title":"Ann Oncol"},{"issue":"5","key":"2104_CR24","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.ijrobp.2015.01.002","volume":"91","author":"T Tan","year":"2015","unstructured":"Tan T, Lim W, Fong K, et al. Concurrent chemo-radiation with or without induction gemcitabine, Carboplatin, and Paclitaxel: a randomized, phase 2\/3 trial in locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2015;91(5):952\u201360.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2104_CR25","first-page":"128","volume":"37","author":"Y Li","year":"2015","unstructured":"Li Y, Jin F, Wu W, et al. Clinical results of recombinant human endostatin combined with chemoradiotherapy for locally advanced nasopharyngeal carcinoma. Chin J Oncol. 2015;37(2):128\u201332.","journal-title":"Chin J Oncol"},{"issue":"4","key":"2104_CR26","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.ijrobp.2011.09.050","volume":"83","author":"X Jiang","year":"2012","unstructured":"Jiang X, Dai P, Wu J, et al. Effect of recombinant human endostatin on radiosensitivity in patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012;83(4):1272\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"2104_CR27","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s12094-012-0821-3","volume":"14","author":"X Jiang","year":"2012","unstructured":"Jiang X, Dai P, Qiao Y, et al. Clinical study on the recombinant human endostatin regarding improving the blood perfusion and hypoxia of non-small-cell lung cancer. Clin Transl Oncol. 2012;14(6):437\u201343.","journal-title":"Clin Transl Oncol"},{"issue":"41","key":"2104_CR28","doi-asserted-by":"publisher","first-page":"70788","DOI":"10.18632\/oncotarget.19989","volume":"8","author":"J Yao","year":"2017","unstructured":"Yao J, Fan L, Peng C, et al. Clinical efficacy of endostar combined with chemotherapy in the treatment of peritoneal carcinomatosis in gastric cancer: results from a retrospective study. Oncotarget. 2017;8(41):70788\u201397.","journal-title":"Oncotarget"},{"issue":"2","key":"2104_CR29","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3892\/mmr.2012.903","volume":"6","author":"K Zhang","year":"2012","unstructured":"Zhang K, Yang S, Zhu Y, et al. Protection against acute radiation-induced lung injury: a novel role for the anti-angiogenic agent Endostar. Mol Med Rep. 2012;6(2):309\u201315.","journal-title":"Mol Med Rep"},{"issue":"1","key":"2104_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.radonc.2015.02.017","volume":"115","author":"X Wang","year":"2015","unstructured":"Wang X, Hu C, Ying H, et al. Patterns of lymph node metastasis from nasopharyngeal carcinoma based on the 2013 updated consensus guidelines for neck node levels. Radiother Oncol. 2015;115(1):41\u20135.","journal-title":"Radiother Oncol"},{"issue":"3","key":"2104_CR31","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.4143\/crt.2018.595","volume":"51","author":"Y Feng","year":"2019","unstructured":"Feng Y, Cao C, Hu Q, et al. Prognostic value and staging classification of lymph nodal necrosis in nasopharyngeal carcinoma after intensity-modulated radiotherapy. Cancer Res Treat. 2019;51(3):1222\u201330.","journal-title":"Cancer Res Treat"},{"key":"2104_CR32","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.radonc.2020.11.011","volume":"155","author":"S Liang","year":"2021","unstructured":"Liang S, Chen L, Yang X, et al. Influence of tumor necrosis on treatment sensitivity and long-term survival in nasopharyngeal carcinoma. Radiother Oncol. 2021;155:219\u201325.","journal-title":"Radiother Oncol"},{"issue":"2","key":"2104_CR33","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1177\/01945998211008887","volume":"166","author":"M Karakurt Ery\u0131lmaz","year":"2022","unstructured":"Karakurt Ery\u0131lmaz M, Kad\u0131yoran C. Prognostic significance of radiologic extranodal extension in nasopharyngeal cancer. Otolaryng Head Neck. 2022;166(2):321\u20136.","journal-title":"Otolaryng Head Neck"},{"issue":"9","key":"2104_CR34","doi-asserted-by":"publisher","first-page":"929","DOI":"10.3727\/096504021X16318716607908","volume":"28","author":"H Lu","year":"2022","unstructured":"Lu H, Wu Y, Liu X, et al. Endostar, an antiangiogenesis inhibitor, combined with chemoradiotherapy for locally advanced cervical cancer. Oncol Res. 2022;28(9):929\u201344.","journal-title":"Oncol Res"},{"key":"2104_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.radonc.2018.10.032","volume":"131","author":"Y Zhai","year":"2019","unstructured":"Zhai Y, Ma H, Hui Z, et al. HELPER study: A phase II trial of continuous infusion of endostar combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer. Radiother Oncol. 2019;131:27\u201334.","journal-title":"Radiother Oncol"},{"issue":"1","key":"2104_CR36","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s13014-020-01646-9","volume":"15","author":"S Zhang","year":"2020","unstructured":"Zhang S, Han C, Sun L, et al. Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis. Radiat Oncol. 2020;15(1):205.","journal-title":"Radiat Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02104-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-022-02104-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02104-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T20:03:22Z","timestamp":1659125002000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-022-02104-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,29]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2104"],"URL":"https:\/\/doi.org\/10.1186\/s13014-022-02104-4","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,29]]},"assertion":[{"value":"22 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the Declaration of Helsinki. All methods were performed in accordance with the relevant guidelines and regulations. The study was approved by the Research Ethics Committee of Guangxi Medical University (NO. 2022-KY-E-(170)). Individual consent was waived due to the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declared that they have no competing interests with this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"135"}}